

## COLON DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON  
ROOM: ROSSETTI  
SATURDAY MAY 4, 2019, 7:45 AM – 09:30 AM

CO-CHAIRS : DR. DEREK JONKER & DR. SHARLENE GILL  
SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

### **CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

### **Learning Objectives:**

- To identify and address, through clinical and translational research, the disease burden associated with malignancies of the colon in Canada.
- To identify clinical trial research opportunities in malignancies of the colon within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to malignancies of the colon.
- To integrate and apply new clinical trial methodologies in malignancies of the colon in the Canadian Cancer Trials Group research agenda.
- To provide a learning and mentoring environment supportive to new investigators.

7:45 am	Welcome	Dr. D. Jonker Dr. S. Gill
7:50 am	Guest Presentation – Guardant Health Cell-free DNA Analysis to Assess Tumor Genomics	Ms L. Kiedrowski
8:10 am	Concept: Molecular Platform in CRC Study	Dr. J. Loree
8:20 am	CRC.9 (NRG G11643): Phase II/III study of circulating tumor DNA as a predictive marker for response to adjuvant chemotherapy in patients with stage II colon cancer (COBRA)	Dr. J. Loree Dr. H. Lim
8:30 am	UCGI 28 PANIRINOX: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer	Dr. D. Jonker

8:40 am	ARRoW: Anti-EGFR Rechallenge of RAS and BRAF Wildtype Metastatic Colorectal Cancer Previously Responding to Anti-EGFR Therapy	Dr. J. Loree
8:50 am	CO.26: A Phase II/III Trial of MEDI4736 plus Tremelimumab vs Best Supportive Care as therapy in Chemotherapy-Refractory Advanced Colorectal Adenocarcinoma	Dr. E. Chen
8:57 am	Concept: anti-PD-L1 plus anti-CTLA4 versus Best Supportive Care (BSC) in patients with Microsatellite Stable (MSS)/Proficient Mismatch Repair (pMMR) Refractory Advanced Colorectal Cancer (CRC) and high Tumour Mutational Burden (TMB)	Dr. D. Jonker
9:05 am	Concept: TAS-102 + Durvalumab + Tremelimumab versus TAS-102 in patients with Refractory Advanced Colorectal Cancer (CRC)	Dr. P. Tang
9:10 am	CO.27(IROCAS): A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for high Risk Stage III Colon Cancer in Adjuvant Setting	Dr. S. Gill
9:15 am	CO.21 (CHALLENGE): A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival In Patients with Early Stage Colon Cancer: A Randomized Controlled Trial (Challenge)	Dr. C. Booth
09:20 am	Intergroup Task Force Update	Dr.D. Jonker Dr. S. Gill
09:30 am	Meeting Adjourned	